LG Chem Signs $855 Million License Deal With Rhythm Pharmaceuticals
LG Chem signed a $855 million license-out deal with Rhythm Pharmaceuticals, with a $450 million upfront payment and $405 million in milestones.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to Reuters, LG Chem has signed a license-out agreement with Rhythm Pharmaceuticals. The total value of the deal is $855 million.
Of that, $450 million is an upfront payment and $405 million is tied to milestone payments.
why it matters
For the broad market this is a local story: it matters mainly to shareholders of LG Chem and Rhythm Pharmaceuticals, who get a reference point for the value of the licensed rights.
market impact
LG Chem and Rhythm Pharmaceuticals: the $855 million deal mainly affects their own shares
tags
instruments
sources
- Lg Chem Signs $855 Million License-Out Agreement With Rhythm Pharmaceuticals — Reuters, 3 November 2026 at 01:53 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗